Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib res...
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
About this item
Full title
Author / Creator
Cretella, Daniele , Saccani, Francesca , Quaini, Federico , Frati, Caterina , Lagrasta, Costanza , Bonelli, Mara , Caffarra, Cristina , Cavazzoni, Andrea , Fumarola, Claudia , Galetti, Maricla , La Monica, Silvia , Ampollini, Luca , Tiseo, Marcello , Ardizzoni, Andrea , Petronini, Pier Giorgio and Alfieri, Roberta R
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
HER-2 represents a relatively new therapeutic target for non small cell lung cancer (NSCLC) patients. The incidence for reported HER-2 overexpression/amplification/mutations ranges from 2 to 20% in NSCLC. Moreover, HER-2 amplification is a potential mechanism of resistance to tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-...
Alternative Titles
Full title
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4058446
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4058446
Other Identifiers
ISSN
1476-4598
E-ISSN
1476-4598
DOI
10.1186/1476-4598-13-143
